The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study (The CAPS-PAH Study)
Phase of Trial: Phase IV
Latest Information Update: 04 Mar 2016
At a glance
- Drugs Ambrisentan (Primary) ; Spironolactone (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms CAPS-PAH
- 07 Jun 2017 Biomarkers information updated
- 04 Mar 2016 Last checked against ClinicalTrials.gov record.
- 01 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.